COMPANY OVERVIEW

OncoResponse discovers and develops highly targeted and immuno-oncology therapeutic antibodies against novel cancer targets. Our most advanced program, ONCR-201 is an anti-EMP2 fully-human monoclonal antibody being developed for female malignancies.

---

LOCATION

Houston, TX, USA

Seattle, WA, USA

---

THERAPEUTIC AREAS

Immunology

Oncology

---

WEBSITE

https://www.oncoresponseinc.com

---

CAREER WEBSITE

None

---

SOCIAL MEDIA

---

INVESTORS

---

---

PRESS RELEASES

Nov 11, 2022

OncoResponse Announces Preclinical Data Highlighting OR2805 Discovery from Elite Responder Platform and OR502 anti-LILRB2 Antibody at SITC 2022

Feb 15, 2022

Oxford Finance Announces the Closing of a $50 Million Credit Facility With OncoResponse

Nov 2, 2021

OncoResponse Announces Initiation of Phase 1 Trial of OR2805 - Human Monoclonal Antibody Derived from Elite Responder to Cancer Immunotherapy - in Patients with Advanced Cancer

Mar 31, 2021

OncoResponse Raises $40.6 Million Series C Financing

Sep 11, 2018

OncoResponse Raises $40 Million in Series B Financing

For More Press Releases

---